Announcement PDF Building a Portfolio of Differentiated Specialty Therapies 1 Investor Update | March 2026 Important Notice and Disclaimer 2 ‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd (Company or LTP) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation. ‣ Not an offer: This presentation is NOT a recommendation, offer or invitation to subscribe for or purchase LTP securities. This presentation is not exhaustive and does not contain all of the information a potential investor, or their professional advisers would require, and it does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth), and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. This presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed publicly in the United States. See the section of this presentation captioned “International Offer Jurisdictions” for more information. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy any securities in any jurisdiction. Any failure to comply with such restrictions could constitute a violation of applicable securities laws. ‣ Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision. ‣ Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. ‣ Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. ‣ LTR Pharma Limited ACN 644 924 569 Executive Summary 3 Differentiated Lead Program – SPONTAN / ROXUS Rapid-acting intranasal PDE5 therapy demonstrating 5x faster absorption versus oral tablets at half the dose, with a validated safety and tolerability profile. Dual U.S. Pathway Strategy Advancing SPONTAN via the 505(b)(2) regulatory pathway following successful Pre-IND engagement. In parallel, progressing commercial discussions to support U.S. launch of ROXUS through the personalised medicine (503A) channel. Early Commercial Validation (Australia) 1,000+ prescriptions under the TGA Special Access Scheme (SAS), supporting prescriber adoption and expanding real-world safety and efficacy data. Strategic Partnerships Co-development agreement with Aptar Pharma (Nasdaq). Commercial manufacturing with Mayne Pharma (ASX). National distribution via EBOS/Symbion (ASX). Funded Through Key Milestones $25.9M cash, zero debt, funding Phase II data readout and continued regulatory and commercial advancement.1 LTR Pharma: Late-Stage Pharmaceutical Platform with Validated Early Market Access 1. Source: Appendix 4C for quarter ended 31 December 2025. Cash figures in Australian Dollars. Market Inefficiency: High Discontinuation and Delayed Onset Global Erectile Dysfunction Treatment Market 5 Global ED drug market estimated at ~US$5B annually1 Oral PDE5 inhibitors currently dominate prescribing High discontinuation rates (>50%) reported with oral PDE5 inhibitors due to delayed onset, inconsistent response and tolerability2 Rapid growth in telehealth prescribing channels Opportunity for differentiated therapies with faster onset and alternative delivery Potential adoption in difficult-to-treat ED segments (e.g., post-prostatectomy, performance anxiety, BPH) 1) Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 2) Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation," Journal of Sexual Medicine, May 2012. Prevalence of ED with individuals with cardiovascular risk factors, hypertension and diabetes, is reported as high as 50% Understanding the Market Need 6 A significant healthcare challenge affecting relationships and quality of life Physical causes ‣ Heart health ‣ Hormone balance ‣ Prostate Cancer ‣ Diabetes ‣ Medical treatments ‣ Hair loss ‣ Weight loss ‣ Antidepressants Psychological Impact ‣ Relationship problems ‣ Mental wellbeing ‣ Day to day stress 60% 50% Growing prevalence with age impacts quality of life Of men over 45 experience ED2 Stop purchasing PDE5 tablets1 1) Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation," Journal of Sexual Medicine, May 2012. 2) Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 First and only PDE5 nasal spray, available now in Australia under TGA early access. Product Main Brand(s) Time before sexual activity for dose Approval Date (US) Generic availability Sildenafil Viagra 1 hour+ 1998 Yes Tadalafil Cialis 1 hour+ 2003 Yes Vardenafil Levitra, Staxyn 1 hour+ 2003 Yes Avanafil Stendra 30 minutes+ 2012 No Current Treatments 7 Oral Phosphodiesterase-5 (PDE5) inhibitors are first-line treatments Issues with oral PDE5 inhibitors Does not work for 30-35% of patients Long response time of 1 hour + affects spontaneity Adverse reactions in up to 35% of patients = High discontinuation rate Oral PDE5 inhibitors and SPONTAN® Nasal Spray Where SPONTAN Fits in the ED Treatment Landscape 8 Current first-line therapy: Oral PDE5 inhibitors (Viagra, Cialis, Levitra) May offer advantages for patients who do not respond optimally to oral PDE5 inhibitors SPONTAN ® intranasal delivery bypasses first-pass metabolism and enables faster systemic absorption Limitations of oral therapies include delayed onset, food interactions, and high discontinuation rates Rapid onset potential supports more spontaneous use compared with traditional oral treatments Applicable across the broad ED population, particularly for patients seeking faster onset and improved spontaneity, with potential advantages in difficult-to-treat segments such as post-prostatectomy and performance-related ED. in Key Markets 9 As risk factors become more prevalent, so does ED Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 ~30m ~33m ~150m 60.7% of males 45y/o+ USA EU China Aus Solution Parameter SPONTAN® Pivotal Pharmacokinetic Study 11 ‣ SPONTAN® nasal spray achieved rapid absorption and faster onset of action compared to oral PDE5 inhibitors. ‣ SPONTAN® delivered similar bioavailability (Cmax) at half the dose of oral PDE5 inhibitors. ‣ Significantly faster (Tmax) with SPONTAN® in as little as 9 min (avg. 12 min) vs oral (56 min) - longest 2.5 hours. ‣ Confirmed safety and tolerability profile of SPONTAN® vs oral dosing PDE5 Inhibitors. ‣ SPONTAN® demonstrated more consistent dosing than oral PDE5 Inhibitors. ‣ Data to be used in regulatory filings in US, Australia and other key markets. Rapid onset effect, consistent delivery and improved safety profile ‣ Cmax (ng/ml) (5mg) Vardenafil (10mg) oral ‣ 13.0 ‣ 16.7 ‣ Adverse Events ‣ 0 ‣ 1 ‣ Tmax (min) ‣ 12 (range 9-15) 56 (Longest 150) SPONTAN® the Science of Superior Delivery 12 Potency Advantage ‣ Half the dose ‣ Dose-normalised Cmax is 155.6% higher than orals ‣ Consistent effectiveness ‣ Direct bloodstream delivery bypasses liver metabolism Speed Superiority ‣ Tmax: 5x faster than oral tablets ‣ Peak concentration in as little as 9 mins ‣ Average onset: 12 mins vs 56 mins *Based on healthcare professional feedback Time to peak concentration (Tmax) (minutes) Patients can respond in as little as 5 minutes, well before peak concentration is reached* Proven Safety ‣ Validated safety profile ‣ No severe events ‣ Clinically proven Tablets Healthcare Professional Insight 0 20 40 60 Faster and more potent ¹ APCC 2025 Case Series (ASX: 25 Aug 2025) ² Performance-Related ED Observations (ASX: 2 Feb 2026) Australian Early Access Program: Real-World Clinical and Prescriber Validation 13 TGA Special Access Scheme - 1,000+ prescriptions supporting real-world clinical and prescriber validation Prescriber Adoption ‣ 1,000+ prescriptions and growing ‣ Expanding prescriber base ‣ Repeat prescribing behaviour observed Real-World Clinical Data ‣ Published case series (APCC 2025) ‣ Positive patient preference versus oral PDE5 in post-prostatectomy cohort¹ ‣ Positive outcomes in performance-related ED² ‣ Growing real-world safety and efficacy dataset Commercial Infrastructure Established ‣ 600+ pharmacies via Symbion / TerryWhite Chemmart ‣ Telehealth integration underway ‣ Distribution and fulfilment processes operational Why LTR Pharma Can Win in the ED Treatment Market 14 Efficient regulatory strategy via the FDA 505(b)(2) pathway Potential early U.S. market entry via personalised medicine (503A) pathway while advancing toward FDA approval Strategic partnerships supporting development and commercialisation (Aptar, Mayne, EBOS/Symbion) Real-world validation: 1,000+ prescriptions under the Australian TGA Special Access Scheme Clinically differentiated product: SPONTAN demonstrates ~5x faster absorption versus oral PDE5 tablets Intranasal delivery bypasses first-pass metabolism, enabling rapid systemic exposure US Market Strategy 15 Primary Value Pathway – FDA 505(b)(2) ‣ Pre-IND meeting completed with FDA ‣ Agreed development framework ‣ Phase II PK study underway ‣ Single pivotal Phase III Safety and Efficacy study required ‣ CMC and human factors programme progressing with Aptar ‣ Designed to support NDA submission under the 505(b)(2) pathway Complementary Commercial Pathway – ROXUS (503A) ‣ Progressing commercial discussions with U.S. personalised medicine pharmacies and telehealth ‣ Intended to support early market presence ‣ Generates commercial experience and real-world insights ‣ Complimentary to the FDA regulatory programme FDA Regulatory Program Check Points Dua Pathway Approach Pre-IND Meeting CMC, Non-clinical, Clinical Non-Clinical Program (toxicology) Phase II PK Study Phase III Safety & Efficacy NDA submission FDA Review Portfolio Overview and Development Focus 16 Lead Clinical Program ‣ TGA Early Access – ACTIVE ‣ FDA 505(b)(2) regulatory pathway ‣ Phase II PK Study Underway ‣ 503A Commercial Discussions Progressing Early Development OROFLOW – Platform Expansion ‣ Pre-clinical / proof-of-concept Stage ‣ Evaluating additional intranasal indications ‣ Capital prioritised to lead program Strategic Investment LevOmega ‣ Equity Investment – 43% ‣ Focused on development of nature-identical omega-3 products ‣ Separate development pathway and capital structure ‣ Complementary to LTR’s core intranasal programs Validated Platform Supporting Multiple Indications Intranasal Sprays for Erectile Dysfunction Intranasal Spray for Oesophageal Motility Disorders (OMD) Nature-Identical omega-3 Products Strategic Execution Milestones, Partnerships and Regulatory Progress Combination product expertise ‣ Co-development agreement with Aptar Pharma (Nasdaq) ‣ VP7 multidose nasal spray platform ‣ Integrated drug-device development programme Regulatory and development ‣ Extractables study completed ‣ Leachables study underway ‣ Human factors studies progressing ‣ Supporting FDA combination product requirements Global Co-Development Agreement Aptar Pharma 18 Strategic significance ‣ Global supply and FDA expertise ‣ Alignment with 505(b)(2) development pathway ‣ Established pharmaceutical partner Strategic partnership driving regulatory success and market readiness US Market Entry Preparations Cash in Bank $25.9 million Quarterly Operation Cash Outflow $2.8 million Debt Position Zero debt Financial Position 19 Funded Value Inflection Points Completion of Phase II PK Study In progress Ongoing Funded to deliver near-term clinical milestones Source: Appendix 4C for quarter ended 31 December 2025. Cash figures in Australian Dollars. Disciplined capital management supporting clinical and commercial execution Human factors programme Underway Non-clinical toxicology programme Progressing $25.9M cash | Zero debt | Supporting key clinical and regulatory milestones Key Milestones 20 Executing across clinical, regulatory and commercial programmes Achieved ‣ Pre-IND meeting completed with FDA endorsement ‣ Phase II PK dosing commenced ‣ Extractables study completed — all compounds below ICH thresholds ‣ 1,000+ prescriptions under TGA early access ‣ Clinical data published in European Journal of Pharmaceutical Sciences Near-Term (H1 2026) ‣ Phase II PK initial data readout ‣ Human factors study completion ‣ Leachables study completion ‣ Progression of commercial discussions in support of entering the U.S. personalized medicine (503A) pathway. Development Progression (H2 2026+) ‣ Full Phase II data set ‣ Animal toxicology completion ‣ Phase III planning ‣ OROFLOW® proof-of-concept progression ‣ Strategic partnership discussions Clinical proof. Contracted partners. Funded to deliver Why Invest in LTR Pharma 21 Capital and Strategic Position ‣ $25.9M cash, zero debt, disciplined capital allocation. ‣ Partnerships with Aptar (Nasdaq), Mayne (ASX), and EBOS/Symbion (ASX). Clear and Efficient Regulatory Pathway ‣ Advancing via the FDA 505(b)(2) framework following successful Pre-IND engagement, requiring a single Pivotal Phase III study. Early Validation and U.S. Strategy ‣ 1,000+ prescriptions under Australia’s SAS programme supporting prescriber adoption. ‣ Dual U.S. approach: FDA pathway complemented by potential personalised medicine (503A) entry. Clinical Differentiation ‣ SPONTAN / ROXUS demonstrates 5x faster absorption at half the dose versus oral PDE5 tablets, with validated safety and tolerability supported by peer-reviewed publication. Contact investors@ltrpharma.com www.ltrpharma.com Authorised for release by the Board of Directors